Corrigendum: Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines(Scientific Data (2017) 4 (170033) DOI: 10.1038/sdata.2017.33);Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines

Scientific Data

Volumn 4, Issue , 2017, Pages

  Harenza, Jo Lynne ^a   DIamond, Maura A ^a   Adams, Rebecca N ^b   Song, Michael M ^c   Davidson, Heather L ^c   Hart, Lori S ^a   Dent, Maiah H ^a   Fortina, Paolo ^b   Reynolds, C Patrick ^c   Maris, John M ^a,d  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE EXPRESSION PROFILING; GENETICS; HUMAN; MUTATION; NEUROBLASTOMA; TUMOR CELL LINE;

CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HUMANS; MUTATION; NEUROBLASTOMA;

EID: 85016433791     PISSN: None     EISSN: 20524463     Source Type: Journal    
DOI: 10.1038/sdata.2017.183     Document Type: Erratum

References (27)

1. American Childhood Cancer Organization. Special Section: Cancer in Children, Adolescents. ACS Special Report 25-42(2014).
2. Maris, J. M., Hogarty, M. D., Bagatell, R., Cohn, S. L. Neuroblastoma. Lancet 369, 2106-2120 (2007).
3. Murray, M. R., Stout, A. P. Distinctive Characteristics of the Sympathicoblastoma Cultivated in Vitro: A Method for PromptDiagnosis. Am. J. Pathol. 23, 429-441 (1947).
4. Thiele, C. J. in Human Cell Culture 1, 21-53 (Human Cell Culture Lancaster, 1999).
5. Henrich, K.-O., et al. Integrative Genome-Scale Analysis Identifies Epigenetic Mechanisms of Transcriptional Deregulation inUnfavorable Neuroblastomas. Cancer Res. 76, 5523-5537 (2016).
6. Decock, A., Ongenaert, M., Van Criekinge, W., Speleman, F., Vandesompele, J. DNA methylation profiling of primaryneuroblastoma tumors using methyl-CpG-binding domain sequencing. Sci. Data 3, 160004-160011 (2016).
7. Cole, K. A., Huggins, J., LaQuaglia, M. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) asa therapeutic target in neuroblastoma. Proc. Natl. Acad. Sci 108, 3336-3341 (2011).
8. Whiteford, C. C., et al. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res. 67, 32-40 (2007).
9. Keshelava, N., et al. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines tocytotoxic agents by depsipeptide. J. Natl. Cancer Inst. 99, 1107-1119 (2007).
10. Bosse, K. R., Maris, J. M. Advances in the translational genomics of neuroblastoma: From improving risk stratification andrevealing novel biology to identifying actionable genomic alterations. Cancer 122, 20-33 (2016).
11. Kang, M. H., et al. National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicitytesting. Pediatr. Blood Cancer. 56, 239-249 (2011).
12. Ciccarone, V., Spengler, B. A., Meyers, M. B., Biedler, J. L. Phenotypic diversification in human neuroblastoma cells: Expressionof distinct neural crest lineages. Cancer Res. 49, 219-225 (1989).
13. Ross, R. A., Spengler, B. A., Biedler, J. L. Coordinate morphological and biochemical interconversion of humanneuroblastoma cells. J. Natl. Cancer Inst. 71, 741-747 (1983).
14. Chomczynski, P., Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroformextraction. Anal. Biochem. 162, 156-159 (1987).
15. Dobin, A., et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21 (2013).
16. Kim, D., Langmead, B., Salzberg, S. L. HISAT: A fast spliced aligner with low memory requirements. Nat. Methods 12, 357-360 (2015).
17. Love, M. I., Huber, W., Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. GenomeBiol. 15, 550 (2014).
18. Hart, L. S., et al. Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma. Clin. Cancer Res. doi:10. 1158/1078-0432. CCR-16-1131 (2016).
19. Li, B., Dewey, C. N. RSEM: Accurate transcript quantification from RNA-Seq data with or without a reference genome. BMCBioinformatics 12, 323 (2011).
20. Bray, N. L., Pimentel, H., Melsted, P., Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nature Biotechnol 34, 525-527 (2016).
21. Ritchie, M. E., et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
22. Chen, J., Bardes, E. E., Aronow, B. J., Jegga, A. G. ToppGene Suite for gene list enrichment analysis and candidate geneprioritization. Nucleic Acids Res. 37, W305-W311 (2009).
23. Ashburner, M., et al. Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25, 25-29 (2000).
24. Carr, J., et al. High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays. Cancer Genet. Cytogenet. 172, 127-138 (2007).
25. Nair, P. N., McArdle, L., Cornell, J., Cohn, S. L., Stallings, R. L. High-resolution analysis of 3p deletion in neuroblastoma anddifferential methylation of the SEMA3B tumor suppressor gene. Cancer Genet. Cytogenet. 174, 100-110 (2007).
26. Wang, K., et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature 469, 216-220 (2011).
27. Vandesompele, J., et al. Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics. Int. J. Cancer 122, 1177-1182 (2008).